Nurix Therapeutics, Inc. Stock

Equities

NRIX

US67080M1036

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 01:03:20 2024-06-13 pm EDT 5-day change 1st Jan Change
16.84 USD +2.03% Intraday chart for Nurix Therapeutics, Inc. +3.09% +63.13%
Sales 2024 * 71.29M Sales 2025 * 66.83M Capitalization 1.06B
Net income 2024 * -171M Net income 2025 * -224M EV / Sales 2024 * 10.7 x
Net cash position 2024 * 297M Net cash position 2025 * 297M EV / Sales 2025 * 11.4 x
P/E ratio 2024 *
-5.6 x
P/E ratio 2025 *
-4.96 x
Employees 284
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.82%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.03%
1 week+3.09%
Current month+6.89%
1 month+20.77%
3 months+16.26%
6 months+100.18%
Current year+63.13%
More quotes
1 week
14.69
Extreme 14.69
17.25
1 month
14.50
Extreme 14.5
17.28
Current year
7.65
Extreme 7.65
18.12
1 year
4.22
Extreme 4.22
18.12
3 years
4.22
Extreme 4.22
37.43
5 years
4.22
Extreme 4.22
52.38
10 years
4.22
Extreme 4.22
52.38
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 14-09-17
Director of Finance/CFO 58 14-12-31
Chief Tech/Sci/R&D Officer - 21-08-31
Members of the board TitleAgeSince
Director/Board Member 60 21-09-30
Director/Board Member 58 21-09-30
Chief Executive Officer 62 14-09-17
More insiders
Date Price Change Volume
24-06-13 16.84 +2.03% 593 312
24-06-12 16.5 +2.17% 1,250,482
24-06-11 16.15 +5.42% 633,738
24-06-10 15.32 -2.30% 695,307
24-06-07 15.68 -3.98% 322,090

Delayed Quote Nasdaq, June 13, 2024 at 12:48 pm EDT

More quotes
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases. It DELigase is an integrated discovery platform, to identify and advance drug candidates targeting E3 ligases. Its drug candidates include NX-2127, NX-5948 and NX-1607. NX-2127 is an orally bioavailable Brutons tyrosine kinase (BTK) degrader that also degrades cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) for the treatment of relapsed or refractory B-cell malignancies. NX-5948 is an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases. NX-1607 is an oral clinical-stage small molecule drug candidate that inhibits Casitas B-lineage lymphoma proto-oncogene-B (CBL-B).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
16.5 USD
Average target price
24.67 USD
Spread / Average Target
+49.49%
Consensus